Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • German drug regulator...

    German drug regulator finds dirty rooms in Dr Reddy's facility

    Written by supriya kashyap kashyap Published On 2017-11-03T13:07:15+05:30  |  Updated On 3 Nov 2017 1:07 PM IST
    German drug regulator finds dirty rooms in Dr Reddys facility

    A German government's drug regulating agency, which audited one of Dr Reddy's Laboratories manufacturing facilities here, found "dirty rooms and equipment", among other violations, during an inspection.


    According to the inspection report by Central Authority for Supervision of Medicinal Products in Bavaria (GMP/GCP) of the Upper Bavarian government, the inspection was conducted on August 1 at the drug maker's formulation manufacturing unit-2 at Bachupally.


    "Major deficiencies: (only examples are given for sub-items related to 5 major deficiencies)..3. cleaning of rooms and equipment. (9 sub-items) 3.1 dirty rooms and equipment 3.2 integrity of cleaning-documentation 3.3 cleaning-status labeling 3.4 status-label 'clean' of uncleaned equipment 3.5 dedicated-equipment labeling 4. validation of manufacturing process. (4 sub-items)...," the regulator said as nature of non-compliance in its report.


    The drug-maker's German subsidiary betapharm Arzneimittel GmbH had received a communication from the Regulatory Authority of Germany (Regierung von Oberbayern) in August that the regulator had not renewed GMP (good manufacturing practice) compliance certificate of its formulations manufacturing following an inspection.


    "Pending revocation of the non-compliance certification, the plant will not be able to make any further dispatches to European Union until the next inspection, to be initiated by an invitation from Betapharm," Dr Reddy's had earlier informed.


    Dr Reddy's Global Generics segment's revenues from Europe are primarily derived from Germany, the United Kingdom and out-licensing business across Europe. It clocked Rs 207.5 crore revenues from the region for the three months ended June 30, 2017, an increase of 28 percent as compared to the three months ended June 30, 2016.


    The increase was primarily on account of the increase in sales volume of existing products along with new products launched between July 1, 2016 and June 30, 2017, the company had said in filing with US Securities and Exchange Commission.


    When contacted, a company spokesperson refused to comment on the impact of the revenues from Europe following the German regulator's comments.


    The official said they are in "silent period" pending results announcement and hence cannot comment.


    DRL is slated to announce its July-September quarter results on October 31.


    Regierung von Oberbayern also concluded an audit of the company's formulations manufacturing facility in Duvvada, Vishakapatnam, with zero critical and six major observations recently. The products manufactured at the facility are not currently exported to the EU.


    The Duvvada-facility's compliance with the corrective and preventive action plan and other applicable regulations will be reviewed again by the regulator by November 2018 for continuation of the facility's EU-GMP certification, Dr Reddy's had said.

    ArzneimittelDr Reddy'sDRLGMP/GCPOberbayernUS Securities and Exchange Commission
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok